Monitoring for adverse events among patients on tuberculosis therapy

References

[1]  Lowbridge C, Christensen AJ, McAnulty JM. EpiReview: Tuberculosis in NSW, 2009–2011. N S W Public Health Bull 2013; 24 3–9.

[2]  NSW Health. Tuberculosis – Principles for Management of people with Tuberculosis in NSW. Policy Directive PD2008_019. Available at: http://www0.health.nsw.gov.au/policies/pd/2008/pdf/PD2008_019.pdf (Cited 4 February 2013).

[3]  Tekle B, Mariam DH, Ali A. Defaulting from DOTS and its determinants in three districts of Arsizone in Ethiopia. Int J Tuberc Lung Dis 2002; 6 573–9.
| 1:STN:280:DC%2BD38zlvVyisw%3D%3D&md5=b46f28ed001e6c52b174de98ee7c7b5aCAS | 12102295PubMed |

[4]  Fry RS, Khoshnood K, Vdovichenko E, Granskaya J, Sazhin V, Shpakovskaya L, et al. Barriers to completion of tuberculosis treatment among prisoners in St. Petersburg, Russia. Int J Tuberc Lung Dis 2005; 9 1027–33.
| 1:STN:280:DC%2BD2MvovVCksw%3D%3D&md5=cdd0925a72c3545c3cd15d773da60d3fCAS | 16158896PubMed |

[5]  Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000; 356 1255–9.
| Adverse drug reactions: definitions, diagnosis, and management.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD3cXot1agsr8%3D&md5=93915d6e630d4443cccba5db3d444669CAS | 11072960PubMed |

[6]  Marra F, Marra CA, Bruchet N, Richardson K, Moadebi S, Elwood RK, et al. Adverse drug reactions associated with first-line anti-tuberculosis drug regimens. Int J Tuberc Lung Dis 2007; 11 868–75.
| 1:STN:280:DC%2BD2svoslOhtA%3D%3D&md5=38a46aea9e36bb87e754b81b460046bdCAS | 17705952PubMed |

[7]  Schaberg T, Rebham K, Lode H. Risk factors for side-effects of isoniazid, rifampicin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J 1996; 9 2026–30.
| Risk factors for side-effects of isoniazid, rifampicin and pyrazinamide in patients hospitalized for pulmonary tuberculosis.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DyaK28XmvF2iu7Y%3D&md5=16d9643d0cf7e937fa34ac5b938a6681CAS | 8902462PubMed |

[8]  Zierski M, Bek E. Side-effects of drug regimens used in short-course regimens chemotherapy for pulmonary tuberculosis. A controlled clinical study. Tubercle 1980; 61 41–9.
| Side-effects of drug regimens used in short-course regimens chemotherapy for pulmonary tuberculosis. A controlled clinical study.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DyaL3c7ntVWrug%3D%3D&md5=50f322d16ef43aa18084b666fca41068CAS | 6989067PubMed |

[9]  Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003; 167 1472–7.
| Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis.Crossref | GoogleScholarGoogle Scholar | 12569078PubMed |

[10]  Sharma SK, Balamurugan A, Saha PK, Pandey RM, Mehra NK. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during anti-tuberculosis treatment. Am J Respir Crit Care Med 2002; 166 916–9.
| Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during anti-tuberculosis treatment.Crossref | GoogleScholarGoogle Scholar | 12359646PubMed |

[11]  Durand F, Jebrak G, Pessayre D, Fournier M, Bernuau J. Hepatotoxcity of antitubercular drugs. Rationale for monitoring liver status. Drug Saf 1996; 15 394–405.
| Hepatotoxcity of antitubercular drugs. Rationale for monitoring liver status.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DyaK2sXjtFOksQ%3D%3D&md5=be8111fee92c3320904904bdcfa1206fCAS | 8968694PubMed |

[12]  Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167 603–62.
| American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of tuberculosis.Crossref | GoogleScholarGoogle Scholar | 12588714PubMed |

[13]  Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, et al. An official ATS statement: hepatotoxicity of anti-tuberculous therapy. Am J Respir Crit Care Med 2006; 174 935–52.
| An official ATS statement: hepatotoxicity of anti-tuberculous therapy.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD28Xht1SgtLnJ&md5=87cbd0560bb1b03ca5a32badfee462f5CAS | 17021358PubMed |

[14]  Hopewell PC, Pai M, Maher D, Uplekar M, Raviglione MC. International standards for tuberculosis care. Lancet Infect Dis 2006; 6 710–25.
| International standards for tuberculosis care.Crossref | GoogleScholarGoogle Scholar | 17067920PubMed |